O³,O⁶-morphine ester | 61269-42-9

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: O³,O⁶-morphine ester
• 英文别名: 4,5α-epoxy-17-methyl-3,6α-bis-methylcarbamoyloxy-morphin-7-ene；O,O'-bis-methylcarbamoyl-morphine；Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-(5alpha,6alpha)-, bis(methylcarbamate) (ester)；[(4R,4aR,7S,7aR,12bS)-3-methyl-9-(methylcarbamoyloxy)-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] N-methylcarbamate
• CAS: 61269-42-9
• 化学式: C₂₁H₂₅N₃O₅
• 分子量: 399.447
• InChiKey: AGNRIYUGDARSHW-SDPBFRHGSA-N

物化性质

• 沸点：
  557.6±50.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  89.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  异氰酸甲酯 、 吗啡 生成 O³,O⁶-morphine ester
  参考文献：
  名称：

  Papaioannou,G., European Journal of Medicinal Chemistry, 1976, vol. 11, p. 287

  摘要：

  DOI：

文献信息

• Osmotic extented-release dosage form
  申请人：ALZA CORPORATION

  公开号：EP1384471A1

  公开（公告）日：2004-01-28

  A membrane system for use in an extended release dosage form comprises an internal compartment (15) defined by the membrane system, an interior wall (16) surrounding the internal compartment, wherein the fluid permeability of the interior wall is responsive to osmolarity of an osmotic core (18) comprised in the internal compartment, and a fluid-permeable exterior wall (12) surrounding the interior wall.

  一种用于缓释剂型的膜系统，包括由膜系统限定的内室（15）、围绕内室的内壁（16），其中内壁的液体渗透性与内室中渗透核（18）的渗透压有关，以及围绕内壁的液体可渗透外壁（12）。
• COMPOSITION COMPRISING MORPHINE, POLYPYRROLIDONE AND A POLYALKYLENEOXIDE
  申请人：ALZA CORPORATION

  公开号：EP0767663B1

  公开（公告）日：2002-04-03
• EXTENDED RELEASE DOSAGE FORM
  申请人：ALZA CORPORATION

  公开号：EP1059916B1

  公开（公告）日：2005-11-02
• Osmotic extended-release dosage form
  申请人：ALZA Corporation

  公开号：EP1600154B1

  公开（公告）日：2010-11-03
• Extended Release Dosage Form
  申请人：Edgren E. David

  公开号：US20070128279A1

  公开（公告）日：2007-06-07

  A membrane system comprising an interior wall, a fluid-permeable exterior wall surrounding the interior wall and an internal compartment defined by the membrane system, wherein fluid permeability of the interior wall is responsive to osmolarity of an osmotic core within the internal compartment are disclosed. A controlled release dosage form comprising the membrane system and a process for delivering an osmotically active formulation from an osmotic pump over an extended period of time are also disclosed.